Company research
IRADIMED CORP
CIK 1325618Updated Sep 25, 2026
SecurityIRMD · NASDAQ · equity
IRMD price & chart
Loading TradingView…
NASDAQ:IRMD on TradingView ↗About the company
IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patient…
In the news
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference ↗
Recent filings
4 filing
144 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Other Events
Items 8.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 108,776,000Source | 98,325,775Source | 92,156,098Source | 85,513,747Source |
| Property, Plant and Equipment, NetUSD | 23,856,000Source | 16,810,797Source | 9,288,625Source | 2,399,812Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 51,159,000Source | 52,233,907Source | 49,762,198Source | 57,960,864Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 13,667,000Source | 10,556,733Source | 12,224,273Source | 13,274,521Source |
| Inventory, NetUSD | 11,620,000Source | 10,401,889Source | 12,821,194Source | 5,369,233Source |
| Assets, CurrentUSD | 81,203,000Source | 75,242,219Source | 76,001,112Source | 77,489,671Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,757,000Source | 2,049,690Source | 1,193,447Source | 630,960Source |
| Operating Lease, Right-of-Use AssetUSD | — | 154,688Source | 2,043,043Source | 2,205,286Source |
| Other Assets, NoncurrentUSD | 239,000Source | 198,912Source | 181,449Source | 648,672Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 14,158,000Source | 11,507,019Source | 20,735,934Source | 11,840,760Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,000Source | 1,271Source | 1,265Source | 1,259Source |
| Additional Paid in CapitalUSD | 30,386,000Source | 30,026,734Source | 28,160,745Source | 26,407,446Source |
| Retained Earnings (Accumulated Deficit)USD | 64,231,000Source | 56,790,751Source | 43,258,154Source | 47,264,282Source |
| Stockholders' Equity Attributable to ParentUSD | 94,618,000Source | 86,818,756Source | 71,420,164Source | 73,672,987Source |
| Liabilities and EquityUSD | 108,776,000Source | 98,325,775Source | 92,156,098Source | 85,513,747Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 10,180,000Source | 8,512,308Source | 16,327,306Source | 8,553,743Source |
| Operating Lease, Liability, CurrentUSD | — | 153,264Source | 427,963Source | 293,466Source |
| Accounts Payable, CurrentUSD | 1,820,000Source | 1,896,405Source | 1,857,091Source | 1,799,316Source |
| Operating Lease, Liability, NoncurrentUSD | — | 1,424Source | 1,615,080Source | 1,911,820Source |
| Additional Financial Items | ||||
| Dividends Payable, CurrentUSD | — | — | 7,975,997Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 22,480,000Source | 19,234,026Source | 17,192,776Source | 12,828,487Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,166,000Source | 817,656Source | 765,180Source | 670,673Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,919,000Source | 2,524,536Source | 2,186,909Source | 1,394,106Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 3,027,000Source | -1,762,075Source | -841,911Source | 8,240,688Source |
| Increase (Decrease) in InventoriesUSD | 1,377,000Source | -3,126,046Source | 7,468,170Source | 1,308,956Source |
| Increase (Decrease) in Accounts PayableUSD | -76,000Source | -861,618Source | -216,436Source | 1,124,972Source |
| Deferred Income Tax Expense (Benefit)USD | 2,727,000Source | -697,652Source | -1,421,945Source | 64,410Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 24,947,000Source | 25,624,463Source | 13,465,012Source | 10,042,711Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -8,421,000Source | -8,816,786Source | -8,007,167Source | -1,374,997Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 7,765,000Source | 8,005,033Source | 7,440,510Source | 823,019Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 2,561,000Source | 688,160Source | 610,348Source | 293,981Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -17,601,000Source | -14,335,968Source | -13,656,511Source | -12,706,400Source |
| Dividends paid | — | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -1,075,000Source | 2,471,709Source | -8,198,666Source | -4,038,686Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 51,159,000Source | 52,233,907Source | 49,762,198Source | 57,960,864Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 3,923,000Source | 6,511,827Source | 5,351,708Source | 1,711,500Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,919,000Source | 2,524,536Source | 2,186,909Source | 1,394,106Source |
| Amortization of Intangible AssetsUSD | 370,000Source | 232,114Source | 117,047Source | 101,122Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | 8,025Source |
| DepreciationUSD | 796,000Source | 585,542Source | 648,133Source | — |
| Dividends Payable, CurrentUSD | — | — | 7,975,997Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 2,000Source | -42,888Source | -148,842Source | -36,773Source |
| Gain (Loss) on Disposition of AssetsUSD | 203,000Source | -3,871Source | -12,473Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | 8,025Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -37,000Source | -3,871Source | -12,537Source | 1,741Source |
| General and Administrative ExpenseUSD | 17,782,000Source | 15,937,123Source | 15,122,065Source | 10,697,067Source |
| Income Tax Expense (Benefit)USD | 5,881,000Source | 5,041,433Source | 4,545,480Source | 3,352,262Source |
| Inventory Write-downUSD | 47,000Source | 87,641Source | 181,443Source | 55,737Source |
| Investment Income, InterestUSD | 2,009,000Source | 2,193,145Source | 1,864,113Source | 581,852Source |
| Net Income (Loss) Attributable to ParentUSD | 22,480,000Source | 19,234,026Source | 17,192,776Source | 12,828,487Source |
| Nonoperating Income (Expense)USD | 2,214,000Source | 2,310,732Source | 1,702,798Source | 553,104Source |
| Operating ExpensesUSD | 38,177,000Source | 34,385,154Source | 30,122,811Source | 25,654,758Source |
| Other Nonoperating Income (Expense)USD | — | 164,346Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | 29,618Source | 176,744Source | 146,708Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 83,814,000Source | 73,242,121Source | 65,562,296Source | 53,303,145Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | 26,147,000Source | 21,964,727Source | 20,035,458Source | 15,627,645Source |
| Other Nonoperating Income (Expense)USD | — | 164,346Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 28,361,000Source | 24,275,459Source | 21,738,256Source | 16,180,749Source |
| Income Tax Expense (Benefit)USD | 5,881,000Source | 5,041,433Source | 4,545,480Source | 3,352,262Source |
| Net Income (Loss) Attributable to ParentUSD | 22,480,000Source | 19,234,026Source | 17,192,776Source | 12,828,487Source |
| Earnings Per Share, BasicUSD per share | 1.77Source | 1.52Source | 1.36Source | 1.02Source |
| Earnings Per Share, DilutedUSD per share | 1.75Source | 1.5Source | 1.35Source | 1.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 12,722,000Source | 12,670,216Source | 12,602,948Source | 12,562,856Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 12,854,000Source | 12,783,558Source | 12,722,530Source | 12,635,971Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 370,000Source | 232,114Source | 117,047Source | 101,122Source |
| Current Income Tax Expense (Benefit)USD | 3,154,000Source | 5,739,085Source | 5,967,425Source | 3,287,852Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | 569,551Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 2,000Source | -42,888Source | -148,842Source | -36,773Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | 8,025Source |
| General and Administrative ExpenseUSD | 17,782,000Source | 15,937,123Source | 15,122,065Source | 10,697,067Source |
| Gross ProfitUSD | 64,324,000Source | 56,349,881Source | 50,158,269Source | 41,282,403Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 28,361,000Source | — | — | — |
| Investment Income, InterestUSD | 2,009,000Source | 2,193,145Source | 1,864,113Source | 581,852Source |
| Nonoperating Income (Expense)USD | 2,214,000Source | 2,310,732Source | 1,702,798Source | 553,104Source |
| Operating ExpensesUSD | 38,177,000Source | 34,385,154Source | 30,122,811Source | 25,654,758Source |
| Research and Development ExpenseUSD | 2,975,000Source | 2,831,589Source | 2,858,656Source | 2,278,081Source |
| Selling and Marketing ExpenseUSD | 17,420,000Source | 15,616,442Source | 12,142,090Source | 12,679,610Source |
Filing attachments
irmd-20260210xex99d1.htm · 8-K · 2026-02-10
EX-99.1 2 irmd-20260210xex99d1.htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share Reports record revenue of $22.7 million for the fourth quarter of 2025, an increase of $3.3 million, or 17%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.50 and non-GAAP diluted EPS of $0.54 for the fourth quarter of 2025,…
Read attachment ↗irmd-20251205xex99d1.htm · 8-K · 2025-12-08
EX-99.1 2 irmd-20251205xex99d1.htm EX-99.1 Exhibit 99.1 IRADIMED Announces Special Cash Dividend of $0.50 Per Share Orlando, Florida, December 8, 2025 - iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per share of the Company’s outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 17, 2025. The Comp…
Read attachment ↗irmd-20251103xex99d1.htm · 8-K · 2025-11-03
EX-99.1 2 irmd-20251103xex99d1.htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increas…
Read attachment ↗irmd-20250827xex99d1.htm · 8-K · 2025-09-02
EX-99.1 2 irmd-20250827xex99d1.htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION ANNOUNCES BOARD TRANSITION: ANTHONY VUOTO RETIRES, JOE KIANI APPOINTED AS NEW DIRECTOR Orlando, Florida, September 2, 2025 - IRADIMED CORPORATION (“Iradimed” or the “Company”) (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”)-compatible patient monitoring and infusion systems, today announced a Board of Directors (the “Board”) transition. Anthony Vuoto has retired from h…
Read attachment ↗irmd-20250801xex99d1.htm · 8-K · 2025-08-01
EX-99.1 2 irmd-20250801xex99d1.htm EX-99.1 Exhibit 99.1 IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter …
Read attachment ↗irmd-20250529xex99d1.htm · 8-K · 2025-05-29
EX-99.1 2 irmd-20250529xex99d1.htm EX-99.1 IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System Winter Springs, Florida, May 29, 2025 - Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradime…
Read attachment ↗